Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


J&J Hedges On 2025 Pharma Revenue Outlook

Executive Summary

The company admitted it may not meet a goal set in 2021 to reach a $60bn pharmaceutical revenue target in 2025.

You may also be interested in...

J&J’s Growth Plan Calls For Mega-Blockbusters And A Leading Oncology Franchise

Johnson & Johnson laid out long-term revenue growth guidance and plans for its Innovative Medicines pipeline during an R&D day.

J&J Predicts No Stelara Biosimilar Until 2025

After reaching patent settlements with biosimilar drug makers, the company expects to retain exclusivity of its top-selling drug longer than initially expected.

Patents And LOEs Poised To Be Hot Q2 Topics

Novartis and Johnson & Johnson will be the first two big pharmas to release second quarter financial results, and both have faced recent patent case developments for top-selling drugs.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts